Bernichon Emilie, Rancoule Chloé, Vallard Alexis, Langrand-Escure Julien, Mery Benoîte, Guy Jean-Baptiste, Magné Nicolas
Institut de cancérologie Lucien-Neuwirth, département d'oncologie médicale, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France.
Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France; CNRS UMR 5822, laboratoire de radiobiologie cellulaire et moléculaire de Lyon Sud, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France.
Bull Cancer. 2017 May;104(5):462-475. doi: 10.1016/j.bulcan.2017.03.004. Epub 2017 May 3.
Immunotherapy is on the roll. After revolutionary effects in melanoma, immunotherapy is invading other locations. If current treatments, chemotherapies or targeted therapies block one pathway, immunotherapy should be understood as the activation of a whole system. Indeed, oncogenesis process is defined as an escape of the immune system and the stimulation of this system can block the carcinogenic process. The aim of the present review is to describe the place of immunotherapy in the treatment of solid cancers.
免疫疗法正蓬勃发展。在黑色素瘤治疗中取得革命性成效后，免疫疗法正在进军其他领域。如果说当前的治疗方法，如化疗或靶向治疗是阻断一条通路，那么免疫疗法则应被理解为激活整个系统。事实上，肿瘤发生过程被定义为免疫系统的逃逸，而刺激这个系统可以阻断致癌过程。本综述的目的是描述免疫疗法在实体癌治疗中的地位。
